Clarivate Sells Life Sciences Unit to Altaris for $600M

Clarivate (ticker: CLVT) is making a major portfolio move, agreeing to sell its Life Sciences & Healthcare business to Altaris, a private equity firm focused on healthcare investments, for $600 million. It's the kind of deal that signals a company getting serious about trimming down and sharpening its focus on what it does best.

For Clarivate, which is best known for its data, analytics, and insights tools across research and intellectual property markets, shedding the life sciences and healthcare arm could free up capital and management bandwidth. Companies in the data and analytics space have been under pressure from investors to simplify their business models, and this sale looks like a direct response to that kind of thinking.

Read more Bausch Health Canada Adds PrOKEDI Doses to Quebec Drug List →

Altaris, on the other side of the table, is picking up an asset squarely in its wheelhouse. The firm specializes in healthcare-focused investments, so absorbing a life sciences and healthcare data business isn't exactly a stretch for them. For Altaris, it's potentially a chance to grow the division in ways that a larger, more diversified parent company like Clarivate might not have prioritized.

For everyday investors holding CLVT shares, the big question is what Clarivate plans to do with that $600 million. Paying down debt, buying back shares, or reinvesting in core businesses are all possibilities — and the answer will go a long way toward determining whether this deal is a net positive for shareholders. Keep an eye on management commentary for guidance on capital allocation following the close of the transaction.

Continue reading at Yahoo Finance